Effects of radiofrequency ablation combined with TX chemotherapy in treatment of breast cancer patients with liver metastasis
Objective:To observe effects of radiofrequency ablation combined with TX chemotherapy in treatment of breast cancer patients with liver metastasis. Methods:A prospective study was conducted on 92 patients with liver metastasis of breast cancer admitted to this hospital from January 2019 to March 2022. The control group was treated with TX chemotherapy,while the observation group was treated with radiofrequency ablation on the basis of that of the control group. The clinical efficacy,the prognosis[progression-free survival (PFS),recurrence,death],the liver function indexes[alanine aminotransferase (ALT),aspartate aminotransferase (AST)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups. Results:The objective remission rate of the observation group was 47.83％ (22/46),which was higher than 21.74％ (10/46) of the control group,and the difference was statistically significant (P<0.05). After the treatment,the levels of ALT and AST in the two groups were lower than those before treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions:Radiofrequency ablation combined with TX chemotherapy in the treatment of the breast cancer patients with liver metastasis can improve the disease remission rate and reduce the levels of liver function indexes. Moreover,it is superior to simple TX chemotherapy.
Radiofrequency ablationChemotherapyLiver metastasis of breast cancerPrognosisLiver functionAdverse reaction
万方数据
